Phase 3 Trial Shows Apalutamide Plus Hormone Therapy Reduces Metastasis and Death Risk in High-Risk Prostate Cancer
Source Summary
An international phase 3 clinical trial demonstrated that apalutamide, a next-generation androgen-receptor pathway inhibitor, combined with hormone therapy administered before and after prostate cancer surgery reduced the risk of metastasis or death in patients with high-risk localized and locally advanced prostate cancer. A substudy further validated these findings compared with standard treatment.
Why it matters
The trial provides clinical evidence that combining apalutamide with hormone therapy around surgery improves outcomes for high-risk prostate cancer patients compared to standard care.
